These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 21085856)
1. Digoxin serum levels in patients with Chagas' cardiomyopathy and heart failure. Ferrari SJ; Bestetti RB; Cardinalli-Neto A; Bortoluzzi TB Rev Soc Bras Med Trop; 2010; 43(5):496-9. PubMed ID: 21085856 [TBL] [Abstract][Full Text] [Related]
2. Predictors of all-cause mortality in chronic Chagas' heart disease in the current era of heart failure therapy. Theodoropoulos TA; Bestetti RB; Otaviano AP; Cordeiro JA; Rodrigues VC; Silva AC Int J Cardiol; 2008 Aug; 128(1):22-9. PubMed ID: 18258318 [TBL] [Abstract][Full Text] [Related]
3. [Do we use digitalis properly in the management of elderly patients suffering from the signs of chronic heart failure?]. Erdei F; Vendrey R; Dani G; Kovács E; Márk L; Katona A Orv Hetil; 2006 Oct; 147(41):1993-6. PubMed ID: 17120690 [TBL] [Abstract][Full Text] [Related]
4. Association of serum digoxin concentration and outcomes in patients with heart failure. Rathore SS; Curtis JP; Wang Y; Bristow MR; Krumholz HM JAMA; 2003 Feb; 289(7):871-8. PubMed ID: 12588271 [TBL] [Abstract][Full Text] [Related]
5. Effect of gentamicin on serum digoxin level in patients with congestive heart failure. Alkadi HO; Nooman MA; Raja'a YA Pharm World Sci; 2004 Apr; 26(2):107-9. PubMed ID: 15085946 [TBL] [Abstract][Full Text] [Related]
6. Acute effects of digitalis and enalapril on the neurohormonal profile of chagasic patients with severe congestive heart failure. Khoury AM; Davila DF; Bellabarba G; Donis JH; Torres A; Lemorvan C; Hernandez L; Bishop W Int J Cardiol; 1996 Nov; 57(1):21-9. PubMed ID: 8960939 [TBL] [Abstract][Full Text] [Related]
7. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). van Veldhuisen DJ; Man in 't Veld AJ; Dunselman PH; Lok DJ; Dohmen HJ; Poortermans JC; Withagen AJ; Pasteuning WH; Brouwer J; Lie KI J Am Coll Cardiol; 1993 Nov; 22(6):1564-73. PubMed ID: 7901256 [TBL] [Abstract][Full Text] [Related]
8. Frequency of Clinical Monitoring of Serum Concentrations of Digoxin, Potassium, and Creatinine, and Recording of Electrocardiograms in Digoxin-Treated Patients: A Japanese Claims Database Analysis. Ooba N; Sente A; Abe M; Watanabe F; Tsutsumi D; Nakamura K; Nakayama T; Kimura K; Fukuoka N Biol Pharm Bull; 2020 May; 43(5):913-916. PubMed ID: 32132314 [TBL] [Abstract][Full Text] [Related]
9. [Digoxin plasma levels in four different prescription schedules of common use in clinical practice]. Reinbach R; Villa L; Giraudo P; Venegas R; Fernández P Rev Med Chil; 2003 Apr; 131(4):373-80. PubMed ID: 12870231 [TBL] [Abstract][Full Text] [Related]
10. Optimal digoxin concentrations for patients with heart failure. Carbonin P; Zuccalà G JAMA; 2003 May; 289(20):2643; author reply 2643-4. PubMed ID: 12771104 [No Abstract] [Full Text] [Related]
11. [Therapeutic drug monitoring of digoxin in cardiac heart failure outpatients: comparisons of two analytical methods]. Barros IC; Freitas EM; Rassi S; Carneiro WJ; Rodrigues CR; Honório TC; Teixeira Lde S; Rodríguez V; Cunha LC Farm Hosp; 2014 Jan; 38(1):38-43. PubMed ID: 24483858 [No Abstract] [Full Text] [Related]
12. Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas' heart disease. Freitas HF; Chizzola PR; Paes AT; Lima AC; Mansur AJ Int J Cardiol; 2005 Jul; 102(2):239-47. PubMed ID: 15982491 [TBL] [Abstract][Full Text] [Related]
13. Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. Adams KF; Butler J; Patterson JH; Gattis Stough W; Bauman JL; van Veldhuisen DJ; Schwartz TA; Sabbah H; Mackowiak JI; Ventura HO; Ghali JK Eur J Heart Fail; 2016 Aug; 18(8):1072-81. PubMed ID: 27492641 [TBL] [Abstract][Full Text] [Related]
14. Assessment of the appropriateness of serum digoxin concentration measurement in a medical group setting. Orrico KB; Wu M; Wilson AR J Manag Care Pharm; 2011 Nov; 17(9):695-700. PubMed ID: 22050394 [TBL] [Abstract][Full Text] [Related]
15. Digoxin remains useful in the management of chronic heart failure. Dec GW Med Clin North Am; 2003 Mar; 87(2):317-37. PubMed ID: 12693728 [TBL] [Abstract][Full Text] [Related]
16. [Maximal functional capacity, ejection fraction, and functional class in Chagas cardiomyopathy. Are these indices related?]. Mady C; Salemi VM; Ianni BM; Ramires FJ; Arteaga E Arq Bras Cardiol; 2005 Feb; 84(2):152-5. PubMed ID: 15761639 [TBL] [Abstract][Full Text] [Related]
17. QT interval dispersion in patients with chronic heart failure secondary to Chagas' cardiomyopathy: correlation with clinical variables of prognostic significance. Corbucci HA; Haber DM; Bestetti RB; Cordeiro JA; Fioroni ML Cardiovasc Pathol; 2006; 15(1):18-23. PubMed ID: 16414452 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological interventions for treating heart failure in patients with chagas cardiomyopathy. Hidalgo R; Martí-Carvajal AJ; Kwong JS; Simancas-Racines D; Nicola S Cochrane Database Syst Rev; 2012 Nov; 11():CD009077. PubMed ID: 23152267 [TBL] [Abstract][Full Text] [Related]
19. Effects of B-Blockers on outcome of patients with Chagas' cardiomyopathy with chronic heart failure. Bestetti RB; Otaviano AP; Cardinalli-Neto A; da Rocha BF; Theodoropoulos TA; Cordeiro JA Int J Cardiol; 2011 Sep; 151(2):205-8. PubMed ID: 20591516 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic digoxin level in chylous drainage with no detectable plasma digoxin level. Taylor MD; Kim SS; Vaias LJ Chest; 1998 Nov; 114(5):1482-4. PubMed ID: 9824036 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]